Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives
- PMID: 16777780
- DOI: 10.1080/14992020600582117
Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives
Abstract
In order to develop a sensitive audiometric protocol for identifying ototoxicity in children, a retrospective study of 16 children treated with cisplatin and/or carboplatin was performed. Audiometric testing was done by means of pure-tone threshold audiometry (PTA), high-frequency audiometry (HFA), and distortion product otoacoustic emissions (DPOAEs). Cisplatin caused a sensorineural high-frequency hearing loss in the study group compared to the controls (p < 0.01). Sixty-six percent of the cisplatin patients had a grade 2 or 3 ototoxicity. However, ototoxicity was not found in the patients treated with carboplatin. An excellent correlation was found between DPOAE levels and results obtained by audiometry (r = 0.82). Patients exposed to cisplatin are at significant risk for the development of drug-induced sensorineural hearing loss. Because of the several advantages of DPOAEs (noninvasive, objective, rapid, easy to use, sensitive) this method should be added in the audiological follow-up in infants and toddlers.
Similar articles
-
Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.Ear Hear. 2008 Dec;29(6):875-93. doi: 10.1097/AUD.0b013e318181ad99. Ear Hear. 2008. PMID: 18753950 Clinical Trial.
-
Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.J Clin Oncol. 2007 Apr 1;25(10):1190-5. doi: 10.1200/JCO.2006.07.9723. J Clin Oncol. 2007. PMID: 17401008
-
Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.Int J Pediatr Otorhinolaryngol. 2012 Jan;76(1):131-6. doi: 10.1016/j.ijporl.2011.10.020. Epub 2011 Nov 21. Int J Pediatr Otorhinolaryngol. 2012. PMID: 22104469
-
Assessment of hearing in very young children receiving carboplatin for retinoblastoma.Eur J Cancer. 2006 Mar;42(4):492-500. doi: 10.1016/j.ejca.2005.11.004. Epub 2006 Jan 11. Eur J Cancer. 2006. PMID: 16376542 Review.
-
Practical grading system for evaluating cisplatin ototoxicity in children.J Clin Oncol. 2010 Apr 1;28(10):1788-95. doi: 10.1200/JCO.2009.24.4228. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194861 Review.
Cited by
-
Current audiological diagnostics.GMS Curr Top Otorhinolaryngol Head Neck Surg. 2017 Dec 18;16:Doc09. doi: 10.3205/cto000148. eCollection 2017. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2017. PMID: 29279727 Free PMC article. Review.
-
Report on hearing loss in oncology.Braz J Otorhinolaryngol. 2009 Sep-Oct;75(5):634-41. doi: 10.1016/s1808-8694(15)30510-3. Braz J Otorhinolaryngol. 2009. PMID: 19893928 Free PMC article.
-
Comparison of the effectiveness of monitoring Cisplatin-induced ototoxicity with extended high-frequency pure-tone audiometry or distortion-product otoacoustic emission.Korean J Audiol. 2014 Sep;18(2):58-68. doi: 10.7874/kja.2014.18.2.58. Epub 2014 Sep 16. Korean J Audiol. 2014. PMID: 25279227 Free PMC article.
-
Monitoring carboplatin ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma.Int J Pediatr Otorhinolaryngol. 2010 Oct;74(10):1156-63. doi: 10.1016/j.ijporl.2010.07.004. Epub 2010 Jul 29. Int J Pediatr Otorhinolaryngol. 2010. PMID: 20667604 Free PMC article. Clinical Trial.
-
Using the zebrafish lateral line to screen for ototoxicity.J Assoc Res Otolaryngol. 2008 Jun;9(2):178-90. doi: 10.1007/s10162-008-0118-y. Epub 2008 Apr 12. J Assoc Res Otolaryngol. 2008. PMID: 18408970 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical